相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine
Adriana C. Gamboa et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation
Kazuhiro Tanaka et al.
BMC CANCER (2019)
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. G. Casali et al.
ANNALS OF ONCOLOGY (2018)
A review of soft-tissue sarcomas: translation of biological advances into treatment measures
Ngoc T. Hoang et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma
Akira Kawai et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Beatrice Seddon et al.
LANCET ONCOLOGY (2017)
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D. Tap et al.
LANCET ONCOLOGY (2017)
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
Immunotherapy with Single Agent Nivolumab for Advanced Leiomyosarcoma of the Uterus: Results of a Phase 2 Study
Eytan Ben-Ami et al.
CANCER (2017)
Meta-evaluation of meta-analysis: ten appraisal questions for biologists
Shinichi Nakagawa et al.
BMC BIOLOGY (2017)
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma
Scott M. Schuetze et al.
CANCER (2016)
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
Christopher W. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schoffski et al.
LANCET (2016)
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
Olivier Mir et al.
LANCET ONCOLOGY (2016)
A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
Z. Eroglu et al.
BRITISH JOURNAL OF CANCER (2015)
Clinically Relevant Molecular Subtypes in Leiomyosarcoma
Xiangqian Guo et al.
CLINICAL CANCER RESEARCH (2015)
Meta-analysis in clinical trials revisited
Rebecca DerSimonian et al.
CONTEMPORARY CLINICAL TRIALS (2015)
A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial
B. Bui-Nguyen et al.
EUROPEAN JOURNAL OF CANCER (2015)
Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study
Martee L. Hensley et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial
Patricia Pautier et al.
LANCET ONCOLOGY (2015)
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study
H. Gelderblom et al.
EUROPEAN JOURNAL OF CANCER (2014)
A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: An NRG Oncology/Gynecologic Oncology Group Study
Linda R. Duska et al.
GYNECOLOGIC ONCOLOGY (2014)
Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
Sant P. Chawla et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson et al.
LANCET ONCOLOGY (2014)
Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy
A. Santoro et al.
ANNALS OF ONCOLOGY (2013)
A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
P. A. Cassier et al.
BRITISH JOURNAL OF CANCER (2013)
An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
P. Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2013)
Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
Scott M. Schuetze et al.
EUROPEAN JOURNAL OF CANCER (2012)
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
Sant P. Chawla et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas: A Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)
Patricia Pautier et al.
ONCOLOGIST (2012)
Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study
Xavier Garcia-del-Muro et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
Patrick Schoffski et al.
LANCET ONCOLOGY (2011)
Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy
N. Penel et al.
ANNALS OF ONCOLOGY (2010)
Conducting Meta-Analyses in R with the metafor Package
Wolfgang Viechtbauer
JOURNAL OF STATISTICAL SOFTWARE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
Martee L. Hensley et al.
GYNECOLOGIC ONCOLOGY (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
Martee L. Hensley et al.
GYNECOLOGIC ONCOLOGY (2008)
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine lelomyosarcoma: A Gynecologic Oncology Group phase II trial
Martee L. Hensley et al.
GYNECOLOGIC ONCOLOGY (2008)
Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry
Jaime L. Peters et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
Exatecan in pretreated adult patients with advanced soft tissue sarcoma:: Results of a phase II -: Study of the EORTC Soft Tissue and Bone Sarcoma Group
P. Reichardt et al.
EUROPEAN JOURNAL OF CANCER (2007)
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: A brief communication from the New York Phase II consortium
DYS Kuo et al.
GYNECOLOGIC ONCOLOGY (2006)
Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: A Gynecologic Oncology Group study
HJ Long et al.
GYNECOLOGIC ONCOLOGY (2005)
A graphical method for exploring heterogeneity in meta-analyses:: application to a meta-analysis of 65 trials
B Baujat et al.
STATISTICS IN MEDICINE (2002)
分享论文
